Scancell Holdings PLCLSE: SCLP

Scancell Holdings: Result of AGM

· Issued by Scancell Holdings PLC via RNS

Summary by 6ix AI

Scancell Holdings plc said all resolutions put to shareholders at its Annual General Meeting on November 19, 2026 were passed.

Key details

  • Scancell develops ImmunoBody and Moditope active immunotherapies, treatments meant to prompt the body's own immune system to fight cancer.

6ix AI wrote this summary from the release below and checked it against the release.

Scancell Holdings Plc
19 November 2026

19 November 2026

Scancell Holdings plc

(“Scancell”, the “Company” or the “Group”)

Result of Annual General Meeting

Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses. The lead product, inzitagene plasmivec, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

For more information please contact:

Scancell Holdings plc

Phil L’Huillier, CEO

Panmure Liberum (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Emma Earl, Will Goode, Mark Rogers

WG Partners LLP (Joint Broker)

Claes Spang

+44 (0) 20 3705 9330

Investor and media relations

Mandeep Sehmi

mandeepsehmi@scancell.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Scancell Holdings PLC on 6ix

Story so far

Earlier from Scancell

All Scancell news releases